A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a three-dose regimen of the Clade B-based Merck adenovirus serotype 5 HIV-1 Gag/Pol/Nef vaccine in HIV-1 uninfected adults in South Africa.

Trial Profile

A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a three-dose regimen of the Clade B-based Merck adenovirus serotype 5 HIV-1 Gag/Pol/Nef vaccine in HIV-1 uninfected adults in South Africa.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2016

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Phambili
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2016 Results published in the Vaccine
    • 15 Apr 2014 Status changed from suspended to completed, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top